secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001193125-23-239127
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma reports FY2023 net loss of $19.6M; FDA cleared BB-301 IND; completed $30.9M offering
--------------------------------------------------------------------------------

- Net loss $19.6M ($14.12/share) vs $18.2M ($37.88/share) prior year; cash $2.5M at June 30, 2023.
- FDA cleared IND for BB-301 for OPMD in June 2023; 15 subjects enrolled in Natural History Study as of September.
- Closed $30.9M public offering in August 2023 to fund BB-301 clinical development and operations.
- R&D expenses $12.8M (up from $11.3M); expect to dose first BB-301 patient in 2H2023 with interim data in 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523239127/0001193125-23-239127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523239127/d498664d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-239127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer